Anagnostou et al. present an improved predictor of response to immune checkpoint blockade that integrates estimates of tumor mutational burden corrected for tumor purity, RTK genomic alterations, a smoking-related mutational signature and HLA status.
- Valsamo Anagnostou
- Noushin Niknafs
- Victor E. Velculescu
